Middle East And Africa Botulinum Toxin Market Scope And Analysis

Middle East and Africa Botulinum Toxin Market Report Scope

Competitive Landscape and Key Companies:

Organic and inorganic growth strategies have characterized developments in the Middle East and Africa botulinum toxin market. Various companies focus on organic growth strategies such as launches, expansion, enhancement, and relocation. Inorganic growth strategies witnessed in the market were mergers & acquisitions, partnerships, and collaborations. These activities have paved the way for the expansion of businesses and the customer base of Middle Eastern and African botulinum toxin market players.

• In February 2022, Merz Therapeutics announced that it will expand its strategic partnership with Vensica Therapeutics as the Merz Group invests up to US$3 million in the Israeli start-up. This investment follows the strategic license and collaboration agreement signed in 2021 to utilize Merz’s botulinum neurotoxin A (XEOMIN) for the innovative ultrasound-assisted delivery catheter of Vensica. Merz is thus executing its contractually agreed option to participate in Vensica’s Series C financing round and invest further in the start-up. 
• In August 2021, Merz Therapeutics and the Israeli start-up Vensica Therapeutics Ltd., a urology company, announced that they have entered into a strategic license and collaboration agreement to deliver botulinum neurotoxin A (XEOMIN) to the bladder wall by using Vensica’s innovative ultrasound-assisted delivery catheter. By this, Merz Therapeutics becomes the exclusive toxin supplier of any needleless application for urological indications, such as overactive bladder, neurogenic bladder, interstitial cystitis, and other urology indications.

Company Profiles

• Merz Pharma GmbH & Co KGaA
• AbbVie Inc
• Revance Therapeutics Inc
• Ipsen SA
• Medytox Inc
• Evolus Inc
• Hugel Inc
• Lanzhou Institute of Biological Products Co Ltd
• Gufic
• Metabiologics, Inc.